Screener
Intellia Therapeutics NTLA Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337952
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued expenses | 44,334 | 49,862 |
| Current portion of operating lease liability | 23,344 | 26,480 |
| Current portion of deferred revenue | - | 7,290 |
| Total current liabilities | 79,392 | 103,884 |
| Long-term operating lease liability | 50,066 | 66,849 |
| Total liabilities | 129,458 | 170,733 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: |
Item 1. Financial Statements
FAQ
- What is Intellia Therapeutics's total current liabilities?
- Intellia Therapeutics (NTLA) reported total current liabilities of $79.39M in Q2 2026.
- How has Intellia Therapeutics's total current liabilities changed year-over-year?
- Intellia Therapeutics's total current liabilities decreased by 16.9% year-over-year, from $95.5M to $79.39M.
- What is the long-term trend for Intellia Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Intellia Therapeutics's total current liabilities has grown at a 10.1% compound annual growth rate (CAGR), from $64.25M to $103.88M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Intellia Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude